Evaluation of Appropriate Use of SGLT2-inhibitors with Evaluation of Adopted Medicines and Application of Criterion
-
- Samura Masaru
- Department of Pharmacy, Yokohama General Hospital
-
- Ogawa Hisako
- Department of Pharmacy, Yokohama General Hospital
-
- Sennai Mitsuko
- Department of Pharmacy, Yokohama General Hospital
-
- Hori Shintaro
- Department of Pharmacy, Yokohama General Hospital
-
- Yamamoto Ayako
- Department of Pharmacy, Yokohama General Hospital
-
- Koshioka Sakura
- Department of Pharmacy, Yokohama General Hospital
-
- Hirose Naoki
- Department of Pharmacy, Yokohama General Hospital
-
- Sekine Hisakazu
- Department of Pharmacy, Yokohama General Hospital
Bibliographic Information
- Other Title
-
- SGLT2阻害薬に対する院内採用の評価と使用基準の活用による適正使用支援の有用性に関する検討
Description
<p>Information on the efficacy and safety of new medicine is limited because clinical trials are performed in a limited population. Thus, we evaluated Phase III trials and the pharmaceutical and medical device agency's review reports and risk management plans at Yokohama General Hospital. Moreover, pharmacists evaluated the patient applications for new medicine. We support appropriate pharmacotherapy to evaluate adopted medicines through these activities. Moreover, following the adoption of medicines at our hospital, we form criteria for prescribing high-risk medicines and support appropriate pharmacotherapy. In this study, we evaluated and supported the risk factors of sodium glucose cotransporter 2 (SGLT2)-inhibitors as dehydration (particularly in elderly patients for concomitant diuretic use), urinary tract infection, and genital infection for appropriate use. Furthermore, we developed criteria for prescribing SGLT2-inhibitors, at patient limited and evaluating adopted medicines. We established the endpoints of support by pharmacists as the rate of patient inclusion criteria and pharmacists' intervention for patient inclusion criteria. As a result, the rates of patient inclusion criteria were 43.3% (8/17) and 53.3% (8/15) patient limited and evaluating adopted medicines, respectively. After the pharmacists' intervention, SGLT2-inhibitor was not prescribed to one patient with a history of cerebral infarction and congestive heart failure. Furthermore, as a result of consultations and careful administration for fifteen patients by physicians and pharmacists, severe adverse events were not reported in these patients. We suggest that it was effective to support appropriate pharmacotherapy evaluation of adopted medicines and drug information and form criteria for appropriate use at our hospital.</p>
Journal
-
- Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
-
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 43 (2), 80-93, 2017
Japanese Society of Pharmaceutical Health Care and Sciences
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679753283328
-
- NII Article ID
- 130006342165
-
- ISSN
- 18821499
- 1346342X
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed